Abstract Body

Circulating oxidized LDL (oxLDL) levels are elevated in HIV-infected patients and have been associated with subclinical atherosclerosis.  Statins reduce plaque on coronary computed tomography angiography (cCTA) in HIV-infected individuals but whether this effect is related to changes in oxLDL is unknown.  Thus, we investigated the impact of statins on serum oxLDL and the relationship between changes in oxLDL and coronary atherosclerosis on cCTA.

This randomized, double-blind, placebo-controlled trial included HIV-infected subjects on stable anti-retroviral therapy with subclinical coronary atherosclerosis and LDL-cholesterol < 130 mg/dL.  Subjects were assigned to treatment with either atorvastatin or placebo for 12 months.  Subjects underwent cCTA and measurements of serum oxLDL, sCD14, sCD163, lipoprotein phospholipase A2 (Lp-PLA2), and fasting lipids including direct LDL at baseline and end of the study.  Multivariate regression modeling was performed to examine the effects of change in oxLDL on change in non-calcified plaque volume, controlling for baseline CD4 count, log viral load, 10-year Framingham risk, and change in direct LDL.

Forty HIV-infected subjects were enrolled and assigned to placebo (n=21) or atorvastatin (n=19).  There was no difference in serum oxLDL at baseline between the two groups.  After 12 months, serum oxLDL decreased -22.7% [95% CI -28.7 to -16.7] in the atorvastatin group and increased 7.5% [95% CI -3.3 to 18.4] in the placebo group (p < 0.0001 for comparison of change between groups).  Change in oxLDL, but not direct LDL, significantly correlated with changes in non-calcified plaque volume, total plaque volume, and high risk coronary plaque features of positive remodeling and low attenuation (Table 1).  The relationship between changes in oxLDL and non-calcified plaque volume was independent of the baseline 10-year Framingham risk, CD4 count, viral load, and change in direct LDL. Change in oxLDL was strongly related to change in Lp-PLA2 (r=0.34, p=0.04) but not other immune markers in our study.

Statins significantly reduce oxLDL levels in HIV-infected patients, and reductions in oxLDL relate strongly to improvements in coronary atherosclerosis, independent of traditional cardiovascular risk factors.  Reductions in oxLDL, via effects on arterial inflammation, may be one mechanism through which statins improve atherosclerosis in HIV-infected individuals.